The Enterprise Value as of September 2024 (TTM) for RenovoRx, Inc. (RNXT) is 14.41M

According to RenovoRx, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 14.41M. This represents a change of -12.10% compared to the average of 16.39M of the last 4 quarters.

RenovoRx, Inc. (RNXT) Historical Enterprise Value (quarterly & annually)

How has RNXT Enterprise Value performed in the past?

The mean historical Enterprise Value of RenovoRx, Inc. over the last ten years is 40.46M. The current 14.41M Enterprise Value has changed 3.46% with respect to the historical average. Over the past ten years (40 quarters), RNXT's Enterprise Value was at its highest in in the March 2021 quarter at 62.88M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

RenovoRx, Inc. (RNXT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of RenovoRx, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

RenovoRx, Inc. (RNXT) Average Enterprise Value

How has RNXT Enterprise Value performed in the past?

The current Enterprise Value of RenovoRx, Inc. (RNXT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

RenovoRx, Inc. (RNXT) Enterprise Value vs. Peers

How is RNXT’s Enterprise Value compared to its peers?

RenovoRx, Inc.’s Enterprise Value is greater than Axcella Health Inc. (-7493000.00), greater than Adial Pharmaceuticals, Inc. (3.87M), greater than Better Therapeutics, Inc. (7.71M), greater than Pasithea Therapeutics Corp. (-3926976.00), less than ZIVO Bioscience, Inc. (40.97M), greater than Quoin Pharmaceuticals, Ltd. (-338152.00), greater than ARCA biopharma, Inc. (1.56M), less than Nutriband Inc. (43.49M), less than Longeveron Inc. (19.03M), greater than Virax Biolabs Group Limited (8.94M), less than Anebulo Pharmaceuticals, Inc. (49.05M), greater than SAB Biotherapeutics, Inc. (13.85M), greater than Monopar Therapeutics Inc. (9.05M), less than Eledon Pharmaceuticals, Inc. (76.53M), less than Tempest Therapeutics, Inc. (23.41M), less than Ikena Oncology, Inc. (47.83M), less than Catalyst Biosciences, Inc. (19.42M),

Build a custom stock screener for RenovoRx, Inc. (RNXT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RenovoRx, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

RenovoRx, Inc. (RNXT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like RenovoRx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.